Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSonepiprazole
说明： Selective D4 antagonist
别名： PNU 101387,U 101387
化学名： 4-[4-[2-[(1S)-3,4-Dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinyl]-benzenesulfonamide
纯度： ≥98% (HPLC)
生物活性 for Sonepiprazole
Sonepiprazole is a selective, high affinity antagonist for the rat and human dopamine D4 receptor (Ki = 10 nM). Exhibits low affinity at other monoamine receptors (Ki > 2000 nM). Induces c-fos gene expression in medial prefrontal cortex in a similar manner to clozapine (Cat. No. 0444). Brain penetrant and orally available.
许可信息
Sold for research purposes under agreement from Pfizer Inc.
技术数据 for Sonepiprazole
| 分子量 | 401.52 |
| 公式 | C21H27N3O3S |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 170858-33-0 |
| PubChem ID | 133079 |
| InChI Key | WNUQCGWXPNGORO-NRFANRHFSA-N |
| Smiles | O=S(C1=CC=C(N2CCN(CC[C@H]3C(C=CC=C4)=C4CCO3)CC2)C=C1)(N)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for Sonepiprazole
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 40.15 | 100 |
制备储备液 for Sonepiprazole
以下数据基于产品分子量 401.52。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.49 mL | 12.45 mL | 24.91 mL |
| 5 mM | 0.5 mL | 2.49 mL | 4.98 mL |
| 10 mM | 0.25 mL | 1.25 mL | 2.49 mL |
| 50 mM | 0.05 mL | 0.25 mL | 0.5 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for Sonepiprazole
参考文献 for Sonepiprazole
参考文献是支持产品生物活性的出版物。
Merchant et al (1996) Pharmacological characterization of U-101387, a DA D4 receptor selective antagonist. J.Pharmacol.Exp.Ther. 279 1392 PMID: 8968364
If you know of a relevant reference for Sonepiprazole, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: Sonepiprazole, Sonepiprazole supplier, Sonepiprazole, selective, dopamine, antagonists, D4, receptors, dopaminergic, U101387, PNU101387, pfizer, PNU, 101387, U, Receptors, 4185, Tocris Bioscience
1 篇 Sonepiprazole 的引用文献
引用文献是使用了 Tocris 产品的出版物。 Sonepiprazole 的部分引用包括：
Nagata et al (2019) Blockade of multiple monoamines receptors reduce insulin secretion from pancreatic β-cells. Sci Rep 9 16438 PMID: 31712714
您是否知道使用了 Tocris Sonepiprazole 的优秀论文？ 请告知我们.
Sonepiprazole 的评论
目前没有该产品的评论。 Be the first to review Sonepiprazole and earn rewards!
Have you used Sonepiprazole?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.